266. Familial mediterranean fever Clinical trials / Disease details
Clinical trials : 28 / Drugs : 22 - (DrugBank : 5) / Drug target genes : 14 - Drug target pathways : 59
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-004505-13-DE (EUCTR) | 27/11/2017 | 21/08/2017 | Tocilizumab for the Treatment of Familial Mediterranean Fever | Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean Fever | Adult patients with Familial Mediterranean Fever, who have active disease MedDRA version: 20.0;Level: PT;Classification code 10016207;Term: Familial mediterranean fever;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: RoActemra® 20mg/ml Konzentrat INN or Proposed INN: INN-Tocilizumab Other descriptive name: TOCILIZUMAB | University Hospital Tuebingen | NULL | Not Recruiting | Female: yes Male: yes | 30 | Phase 2 | Germany |